Category: Tysabri

Immunological Markers of Optimal Response to Natalizumab (Tysabri) in Multiple Sclerosis

Luisa M. Villar, PhD; María I. García-Sánchez, PhD; Lucienne Costa-Frossard, MD; Mercedes Espiño, PhD; Ernesto Roldán, PhD; Dolores Páramo, MD; Miguel Lucas, PhD;Guillermo Izquierdo, …

Stuart Schlossman

An MS Patient’s story on PML

Angela created the video found here in October 2010.  This video is very informative and so, I needed to share…

Stuart Schlossman

Phase 3b Trial Evaluates Tysabri as MS Treatment for Secondary Progressive MS (SPMS)

Biogen Idec and Elan Corporation announced a global Phase 3b study that is being conducted to evaluate the effectiveness of…

Stuart Schlossman

FDA approves test to screen Tysabri patients

The Food and Drug Administration on Friday approved a new diagnostic test to help identify patients who have an increased…

Stuart Schlossman

The FDA has approved the first test for assessing the risk of progressive multifocal leukoencephalopathy (PML) in patients on natalizumab (Tysabri)

By Kristina Fiore, Staff Writer, MedPage Today Published: January 20, 2012 SOURCE: Medical News Today The Stratify JCV Antibody ELISA test screens…

Stuart Schlossman

Study Shows Potential of Lab Test to Detect Virus Which Causes PML in People with MS – ongoing study may help identify risk for PML in people treated with natalizumab

Biogen Idec researchers have published results on a blood test that detects antibodies to the JC virus, the virus responsible…

Stuart Schlossman

Natalizumab an Option for Pediatric MS?

November 7, 2011 (Amsterdam, the Netherlands) — A new study suggests that natalizumab (Tysabri, Biogen Idec/Elan) may be an effective…

Stuart Schlossman

While Copaxone and Interferon-Betas Continue to Dominate Treatment in MS, Tysabri Shows Modest Increase in First-Line Use

BURLINGTON, Mass., Nov 02, 2011 (BUSINESS WIRE) — Decision Resources, one of the world’s leading research and advisory firms focusing…

Stuart Schlossman

MS Activity Returns Soon After Stopping Natalizumab (Tysabri)

AMSTERDAM – Significant percentages of patients with relapsing-remitting multiple sclerosis who discontinue natalizumab but start another medication experience a return of…

Stuart Schlossman

Stopping natalizumab (Tysabri) to take a medication vacation, may mean renewed disease activity within six months

ECTRIMS: Fast MS Comeback May Ruin Drug ‘Holiday’ This report is part of a 12-month Clinical Context series. By John Gever,…

Stuart Schlossman

Categories

Latest Blog Posts